[HTML][HTML] Romosozumab treatment in postmenopausal women with osteoporosis
F Cosman, DB Crittenden, JD Adachi… - … England Journal of …, 2016 - Mass Medical Soc
Background Romosozumab, a monoclonal antibody that binds sclerostin, increases bone
formation and decreases bone resorption. Methods We enrolled 7180 postmenopausal …
formation and decreases bone resorption. Methods We enrolled 7180 postmenopausal …
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a …
BL Langdahl, C Libanati, DB Crittenden… - The Lancet, 2017 - thelancet.com
Background Previous bisphosphonate treatment attenuates the bone-forming effect of
teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin …
teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin …
The crystallization of monosodium urate
MA Martillo, L Nazzal, DB Crittenden - Current rheumatology reports, 2014 - Springer
Gout is a common crystal-induced arthritis, in which monosodium urate (MSU) crystals
precipitate within joints and soft tissues and elicit an inflammatory response. The causes of …
precipitate within joints and soft tissues and elicit an inflammatory response. The causes of …
Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout
DB Crittenden, RA Lehmann, L Schneck… - The Journal of …, 2012 - jrheum.org
Objective. The ability of antiinflammatory strategies to alter cardiovascular risk has not been
rigorously examined. Colchicine is an antiinflammatory agent that affects macrophages, …
rigorously examined. Colchicine is an antiinflammatory agent that affects macrophages, …
Prevalence of contraindications and prescription of pharmacologic therapies for gout
RT Keenan, WR O'Brien, KH Lee, DB Crittenden… - The American journal of …, 2011 - Elsevier
BACKGROUND: Patients with gout have comorbidities, but the impact of these comorbidities
on treatment has not been studied. METHODS: A total of 575 patients with gout were …
on treatment has not been studied. METHODS: A total of 575 patients with gout were …
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
…, K Yang, YJ Choi, DB Crittenden… - … England Journal of …, 2024 - Mass Medical Soc
Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. …
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. …
FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab
F Cosman, DB Crittenden, S Ferrari… - Journal of bone and …, 2018 - academic.oup.com
Romosozumab is a bone‐forming agent with a dual effect of increasing bone formation and
decreasing bone resorption. In FRActure study in postmenopausal woMen with ostEoporosis …
decreasing bone resorption. In FRActure study in postmenopausal woMen with ostEoporosis …
Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass
TM Keaveny, DB Crittenden… - Journal of Bone and …, 2017 - academic.oup.com
Romosozumab is a monoclonal antibody that inhibits sclerostin and has been shown to
reduce the risk of fractures within 12 months. In a phase II, randomized, placebo‐controlled …
reduce the risk of fractures within 12 months. In a phase II, randomized, placebo‐controlled …
[HTML][HTML] Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study
H Ishibashi, DB Crittenden, A Miyauchi, C Libanati… - Bone, 2017 - Elsevier
Background Romosozumab is a monoclonal antibody that inhibits sclerostin and rapidly
increases bone mineral density (BMD) through a dual effect on bone by increasing bone …
increases bone mineral density (BMD) through a dual effect on bone by increasing bone …
Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome
F Cosman, DB Crittenden, S Ferrari… - Journal of Bone and …, 2018 - academic.oup.com
In the pivotal Fracture Study in Postmenopausal Women with Osteoporosis (FRAME;
NCT01575834), 1 year of the bone‐forming agent romosozumab significantly reduced new …
NCT01575834), 1 year of the bone‐forming agent romosozumab significantly reduced new …